Evogene Total Assets 2012-2021 | EVGN

Evogene total assets from 2012 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Evogene Annual Total Assets
(Millions of US $)
2020 $72
2019 $71
2018 $59
2017 $78
2016 $96
2015 $113
2014 $128
2013 $137
2012 $65
2011 $68
Evogene Quarterly Total Assets
(Millions of US $)
2021-09-30 $83
2021-06-30 $88
2021-03-31 $93
2020-12-31 $72
2020-09-30 $66
2020-06-30 $61
2020-03-31 $65
2019-12-31 $71
2019-09-30 $76
2019-06-30 $53
2019-03-31 $58
2018-12-31 $59
2018-09-30 $64
2018-06-30 $68
2018-03-31 $72
2017-12-31 $78
2017-09-30 $83
2017-06-30 $87
2017-03-31 $92
2016-12-31 $96
2016-09-30 $102
2016-06-30 $106
2016-03-31 $109
2015-12-31 $113
2015-09-30 $116
2015-06-30 $120
2015-03-31 $123
2014-12-31 $128
2014-09-30 $130
2014-06-30 $132
2014-03-31 $134
2013-12-31 $137
2013-09-30 $60
2013-06-30 $62
2013-03-31 $63
2012-12-31 $65
2012-09-30 $64
2012-06-30 $65
2012-03-31 $67
2011-12-31 $68
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.049B $0.001B
Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $122.991B 7.77
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.439B 21.07
Biohaven Pharmaceutical Holding (BHVN) United States $7.159B 0.00
Arcus Biosciences (RCUS) United States $3.161B 0.00
Emergent Biosolutions (EBS) United States $2.298B 8.26
ADC Therapeutics SA (ADCT) Switzerland $1.545B 0.00
Myovant Sciences (MYOV) United Kingdom $1.443B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.348B 0.00
SQZ Biotechnologies (SQZ) United States $0.329B 0.00
Enzo Biochem (ENZ) United States $0.163B 16.00